, 6 patients were admitted for febrile neutropenia, and 3 cases of nonfatal Pneumocystis jiroveci were seen. 13 , 14 In a Japanese case series of 10 patients, a less-intensive regimen of ATRA, 6-MP, and MTX was used for maintenance, and no patients
Search Results
Edmond Marzbani and Elihu Estey
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes, and Fernando Rivera
overall and grade 3/4 toxicities in comparison with doublets ( Table 3 ), particularly with more grade 3/4 anemia, stomatitis, febrile neutropenia (10.4% vs 6.5%), hepatic toxicity (15.8% vs 9.2%), and toxicity-related hospitalization (30.7% vs 22
Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Oxana V. Crysler, Neel Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, CGC, and Deborah A. Freedman-Cass
uninfected counterparts to infectious complications after chemotherapy, and low CD4+ T-cell counts appear to increase the risk of febrile neutropenia. 47 Furthermore, data show that certain chemotherapy regimens can cause a sustained drop in CD4+ T
Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer, and Deborah A. Freedman-Cass
risk. 61 PLWH may be more susceptible to infectious complications after chemotherapy than their uninfected counterparts, 62 and low CD4+ T-cell counts appear to increase the risk of febrile neutropenia. 63 Furthermore, data show that certain
Michael Cecchini, Jeffrey Sklar, and Jill Lacy
-line FOLFIRINOX. After 38 weeks, imaging again showed progression of hepatic metastases. He received third-line therapy with docetaxel and irinotecan for 2 weeks, but this therapy was complicated by febrile neutropenia. A tumor specimen from the
Justine M. Kahn and Melissa Beauchemin
. Blood 2011 ; 117 : 2596 – 2603 . 10.1182/blood-2010-05-285379 21079154 32. Wright JD , Neugut AI , Ananth CV , Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes . JAMA Intern
Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Z. Kidwai, Dwight D. Kloth, Eric H. Kraut, Gary H. Lyman, Sudipto Mukherjee, Lia E. Perez, Rachel P. Rosovsky, Vivek Roy, Hope S. Rugo, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, and Pamela S. Becker
resources page ( https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf ). 13 We have compiled the following in-depth description of the rationale and evidence supporting our recommendations. Avoidance and Treatment of Neutropenia Febrile neutropenia
Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer, and Maoko Naganuma
neutropenia (70%), thrombocytopenia (45%), anemia (18%), and febrile neutropenia (15%). 17 Lenalidomide was administered using different dosing schedules in these earlier studies. In one study, patients initially received lenalidomide at the 25-mg-daily dose
Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo
%), red blood cell transfusions (47%), and arrhythmias (4%). Similarly, Delarue et al 4 found an 18% rate of febrile neutropenia and a 4% rate of cardiovascular severe adverse effects, with 13% of all fatalities ascribed to complications of R-CHOP. The
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead, and Rashmi Kumar
.6%) of febrile neutropenia in both arms. Overall survival data from this trial are immature. 24 NCCN Recommendations The NCCN Breast Cancer Panel has included the combination of palbociclib with letrozole as a first-line endocrine therapy option for
